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Abstract
Background: Recent studies have shown that tumors with extensive tumor-infiltrating lymphocytes (TILs) have
a higher probability of pathologic complete response, even in luminal/human epidermal growth factor 2 (HER2)-
negative breast cancer. We compared TIL levels and the 21-gene recurrence score (RS) in estrogen receptor (ER)-
positive/HER2-negative breast cancer.
Methods: We evaluated the percentage of stromal TILs in 198 ER-positive/HER2-negative patients in whom RS was
obtained by examining slides of surgical specimens by standardized methodology proposed by the international
TIL Working Group. TIL levels were categorized as high (≥ 60%), intermediate (11–59%), or low (≤ 10%). All tumors
were treatment-naïve.
Results: Ninety-seven (49.0%), 88 (44.4%), and 13 patients (6.6%) had low, intermediate, and high TIL levels, respectively.
There was a significant but weak correlation between continuous RS and continuous TIL levels (Pearson’s R = 0.201, p = 0.
004). The mean RS was significantly highest in high TIL tumors (17.8 ± 10.7 in low TIL tumors, 19.4 ± 8.7 in intermediate
TIL tumors, and 26.2 ± 8.2 in high TIL tumors; p= 0.014). However, when we compared categorized RS and TIL levels, we
found that tumors with high TIL levels tended to have higher RS (≥ 26) but it was not significant (p = 0.155). Furthermore,
multivariate analysis revealed that high RS was not an independent factor associated with high TIL levels. Chemo-endocrine
therapy was more frequently performed among patients with high TILs and less frequently among those with low or
intermediate TILs (p< 0.001).
Conclusions: Despite of a weak correlation between continuous TIL levels and RS, we found that tumors with high TIL
levels tended to have a higher RS in ER-positive/HER2-negative breast cancer. Further study is warranted considering the
clinical outcomes.
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Background
The presence of tumor-infiltrating lymphocytes (TILs) re-
flects an adaptive anti-tumor immune response [1]. Al-
though the immunogenicity of breast cancer has not been
strongly considered in research or clinical practice, TILs are
emerging as biomarkers for predicting clinical response to
chemotherapy for breast cancer [2–8]. Recent translational
studies from large prospective trials suggest that tumors
with high TIL levels show a superior prognosis compared
to tumors with low TIL levels in breast cancer patients
treated with neoadjuvant or adjuvant chemotherapy [2–8].
The correlation between high TIL levels and improved clin-
ical outcome was most prominent in triple-negative breast
cancer (TNBC) [2, 6–8]. After the initial report from the
BIG2–98 trial, a positive relationship between TIL levels
and clinical outcome in TNBC was validated in independ-
ent cohorts in two clinical trials [2, 6].
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Interestingly, TIL levels have not been shown to be prog-
nostic in patients with estrogen receptor (ER)–positive tu-
mors receiving adjuvant chemotherapy. However, a recent
study reported that patients with a high level of TILs have a
greater chance of obtaining a pathological complete re-
sponse (pCR), even in hormone receptor (HR)-positive/hu-
man epidermal growth factor receptor 2 (HER2)-negative
breast cancers [9]. In addition, a recent meta-analysis
showed that HR-positive/HER2-negative tumors with high
TIL levels at baseline biopsy, prior to chemotherapy, have a
higher probability of pCR (n = 1366) [10].
The 21-gene recurrence score (RS) is derived from a
polymerase chain reaction-based test that examines 16
tumor related genes and 5 reference genes to analyze
cell proliferation, estrogen signaling, and invasion cap-
acity. It has been shown to predict the clinical benefit of
chemotherapy for individuals with ER-positive/HER2-
negative breast cancer [11, 12]. Furthermore, previous
studies have shown that tumors with a high RS have a
higher rate of pCR in the neoadjuvant setting [13, 14].
Both TIL levels and the RS could serve as biomarkers as-
sociated with chemotherapy responsiveness in HR-positive/
HER2-negative breast cancer. Moreover, identifying suitable
patients among those with HR-positive/HER2-negative can-
cers who derive clinical benefit from chemotherapy has
been a critical issue; however, the relationship between the
two markers has not been intensively examined.
In this study, we examined the association between
TIL levels and RS in patients with ER-positive/HER2-




Between August 2011 and April 2017, eligible patients were
identified from the breast cancer database of the Gangnam
Severance Hospital [15]. During the period, 212 patients
underwent Oncotype DX testing. All patients had ER-
positive/HER2-negative breast cancer and did not undergo
NAC. In 198 patients, TIL levels were successfully evaluated
using treatment-naïve surgical specimens. A pathologist
(YJC) reviewed the histologic features by using Hematoxylin
& eosin (H&E)-stained slides for all cases. Histologic grade
for breast cancer was assessed using the Nottingham grad-
ing system [16]. The institutional review board of the Gang-
nam Severance Hospital, approved the study to be in
accordance with guidelines of good clinical practice and the
Declaration of Helsinki. The need for informed consent was
waived under the approval of the institutional review board
due to the retrospective design.
Assessment of TIL levels
Stromal TIL levels were scored according to the guide-
lines for TIL assessment by the TILs Working Group
[1]. H&E-stained whole tumor slides were examined and
scored by a pathologist (YJC). Briefly, the tumor area as
defined by the presence of invasive tumor was evaluated,
and all mononuclear cells, including lymphocytes and
plasma cells but not polymorphonuclear leukocytes,
were scored. Areas outside of the tumor border, around
the intraductal component, and normal lobules were ex-
cluded. Within the tumor border, TILs with crush arti-
facts and necrosis were excluded. For each case, three
representative tumor areas were evaluated for TILs, and
the average score was reported as a percentage. TIL
levels was categorized as high (≥ 60%), intermediate
(11–59%), or low (≥ 10%). The cut-off point was defined
using the criteria suggested by Denkert et al. [10].
Immunohistochemistry
For immunohistochemistry (IHC), antibodies specific for
ER (1:100 clone 6F11; Novocastra, Newcastle upon
Tyne, UK), progesterone receptor (PR; clone 16; Novo-
castra), HER2 (4B5 rabbit monoclonal antibody; Ventana
Medical Systems, Tucson, AZ, USA), and Ki-67 (MIB-1;
Dako, Glostrup, Denmark) were stained using formalin-
fixed, paraffin-embedded tissue sections [17]. Positivity
of ER and PR IHC expression was defined according to
the modified Allred system: positive, Allred score 2–8;
and negative, Allred score 0–1 [18]. All tumors included
in this study had ER positivity (Allred scores ≥3). HER2
status was considered positive with a score of 3+ and
negative with a score of 0 or 1+ [19]. Tumors with a
score of 2+ underwent fluorescent in situ hybridization
analysis according to the manufacturer’s instructions
(PathVysion kit; Vysis, Downers Grove, IL, USA or
HER2 inform; Ventana) [19]. Ki-67 expression was eval-
uated by YJC and displayed presented as a percentage
(range 0–100%) of positive tumor cells.
Oncotype dx assays
The RS is calculated by the Oncotype Dx assay [11, 12].
RS scores are calculated on a scale from 0 to 100 and
derived from the reference-normalized expression mea-
surements of 16 cancer-related genes (Ki67, STK15, Sur-
vivin or BIRC5, CCNB1 or cyclin B1, MYBL2, GRB7,
HER2, ER, PGR, BCL2, SCUBE2, MMP11 or stromelysin
3, CTSL2 or cathepsin L2, GSTM1, CD68, and BAG1)
and five reference genes. Quantitative single gene scores
are determined via reverse transcriptase-polymerase
chain reaction. Expression of each gene was measured in
triplicate and normalized to a set of five reference genes
(beta-actin [ACTB], GAPDH, GUS, RPLPO, and TFRC).
Reference-normalized expression measurements ranged
from 0 to 15, where a one-unit increase approximately
reflects a two-fold increase in RNA.
Tumors were classified into the following categories: low
risk (RS < 18), intermediate risk (RS 18–30), and high risk
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(RS ≥ 31). The RS was also dichotomized with a cutoff of
26 as in the TAILORX trial [20]. The Oncotype Dx assay
was supplied by Genomic Health (Redwood City, CA,
USA) and performed using RNA extracted from formalin-
fixed paraffin-embedded tissue. After a review of
hematoxylin and eosin-stained slides to determine whether
sufficient invasive breast cancer was present and whether
manual microdissection was indicated, RNA was extracted
from the unstained sections. Cases without tumor samples
(i.e., depleted by prior tissue studies) or with cancer cells
occupying < 5% of the section area were excluded from the
assay [11]. All tissues from patients in this study were suc-
cessfully analyzed.
Statistical analysis
The primary objective of this study was to test the correl-
ation between RS and TIL levels. Pearson’s R was calcu-
lated to measure the correlative value between two
continuous scores. Discrete variables were compared
using the χ2 test. Continuous variables were compared
using the Mann-Whitney U and Kruskal-Wallis tests. Stu-
dent’s t-test or one-way analysis of variation (ANOVA)
was used to compare means. The variables with statistical
significance in the univariate analysis were included in the
selection of the full multivariate model, and backward
elimination was taken to arrive at the final model.
The Kolmogorov-Smirnov test was applied to test the
normal distribution of continuous variables, including
RS and TIL levels. The distributions of nonparametric
variables were compared using the Kruskal-Wallis test.
A post-hoc test was performed using the Bonferroni-
corrected Dunn’s procedure. SPSS version 18 (SPSS Inc.,
Chicago, IL, USA) was used to perform the statistical




One hundred ninety-eight patients with ER-positive/HER2-
negative tumors were included in the analyses. Ninety-eight
(50%), 80 (40%), and 20 patients (10%) had a low, inter-
mediate, and high RS, respectively, while 97 (49%), 88
(44%), and 13 patients (7%) had low, intermediate, and high
TIL levels, respectively. The baseline characteristics are pre-
sented in Table 1. The median age of these patients was
49 years (range: 27–75 years). Thirty-four patients had
node-positive disease, and 3 had micrometastasis. No pa-
tient in the study population had a stage higher than IIB.
Clinical and pathological characteristics associated with
TIL levels
Tumors with higher nuclear and histologic grade had
high TIL levels (p < 0.001 and p = 0.001, respectively).
Other characteristics, including tumor burden, PR
expression, and Ki-67 expression, were not associated
with TIL levels.
Correlation between continuous RS and continuous TIL
levels
Pearson’s R test was performed to explore the
relationship between continuous RS and continuous
TIL levels. A weak but significant correlation was ob-
served between the two continuous parameters
(Pearson’s R = 0.201; p = 0.004; Fig. 1).
Comparisons categorized RS and categorized TIL levels
Of the 97 patients with low-TIL tumors, 56 (57.7%) had a
low-RS tumor, 30 (30.9%) had an intermediate-RS tumor,
and 11 (11.3%) had a high-RS tumor (Fig. 2a). Eighty-eight
patients with intermediate-TIL tumors showed a similar
distribution of categorized RS compared to patients with
low-TIL tumors (Fig. 2a). In contrast, among the patients
with high-TIL tumors, the percentage of intermediate RS
was 76.9%, which was significantly higher than that in pa-
tients with low- or intermediate-TIL tumors (p = 0.007).
When we compared TIL levels with dichotomized RS,
tumors with high TIL levels tended to have higher RS
(≥ 26), but it was not significant (Fig. 2b; p = 0.155).
Next, we compared RS distributions according to cate-
gorized TIL levels because both markers were not nor-
mally distributed (p < 0.001 with Kolmogorov-Smirnov
test). The RS distributions differed significantly according
to TIL levels (p < 0.001 with Kruskal-Wallis test; Fig. 3a).
A post-hoc test using the Bonferroni-corrected Dunn’s
procedure showed that high-TIL tumors had significantly
higher median RS than low- or intermediate TIL tumors
(p = 0.001 and p = 0.019, respectively; Fig. 3a). However,
the RS medians did not differ significantly between low-
and intermediate-TIL tumors (p = 0.290, Fig. 3a).
When TIL levels were divided into two groups (low-
or intermediate-TILs versus high TILs), high-TIL tumors
had significantly higher median RS values than low- or
intermediate-TIL tumors (Fig. 3b, p < 0.001 with Mann-
Whitney U test).
Logistic regression analysis to identify high TIL levels
We tried to identify factors associated with high TIL
levels in ER-positive/HER2-negative tumors. Variables
with p < 0.05 on univariate analysis, including nuclear
grade, histologic grade, and RS, were entered as input
variables in multivariate analysis in order to distinguish
factors associated with high TIL levels. Multivariate ana-
lysis revealed that nuclear grade remained the only inde-
pendent variable associated with high TIL level
(Table 2). Nuclear grade demonstrated the highest odds
ratio (OR = 15.025; 95% confidence interval = 2.839–
79.510) for predicting high TIL levels on the multivariate
analysis.
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Association of TIL levels with RS-guided adjuvant therapy
Lastly, we investigated an association of TIL levels with
adjuvant treatment. Based on the RS results, patients
were guided to receive either endocrine therapy (ET)
alone or chemo-endocrine therapy. As a result, all pa-
tients with low RS (n = 98) received ET alone, while all
patients with high RS (n = 20) received chemo-endocrine
therapy (Fig. 4a). Among 80 patients with intermediate
RS, 45 (56.3%) were guided to forego ET alone.
Among patients receiving RS-guided treatments, asso-
ciations between TIL levels and adjuvant treatments
were analyzed. The classification by TIL levels was
Table 1 Baseline characteristics
Low TIL (N = 97) Intermediate TIL (N = 88) High TIL (N = 13) P-value a
Age, median (range) 50 (28–75) 48 (34–74) 50 (27–73) 0.280 b
Histology 0.152
IDC 73 (75.3) 75 (85.2) 13 (100.0)
ILC 14 (14.4) 6 (6.8) 0 (0.0)
Others 10 (10.3) 7 (8.0) 0 (0.0)
pT stage 0.540
T1 65 (67.0) 61 (69.3) 7 (53.8)
T2 32 (33.0) 27 (30.7) 6 (46.2)
pN stage 0.286
N0 84 (86.6) 70 (79.5) 10 (76.9)
N1mi 5 (5.2) 3 (3.4) 0 (0.0)
N1 8 (8.2) 15 (17.0) 3 (23.1)
pStage 0.210
IA 55 (56.7) 50 (56.8) 6 (46.2)
IB 4 (4.2) 2 (2.3) 0 (0.0)
IIA 37 (38.1) 30 (34.1) 5 (38.5)
IIB 1 (1.0) 6 (6.8) 2 (15.4)
Nuclear grade c < 0.001
1 4 (4.1) 5 (5.7) 1 (7.7)
2 79 (81.5) 56 (63.6) 1 (7.7)
3 12 (12.4) 27 (30.7) 11 (84.6)
Unknown 2 (2.0) 0 (0) 0 (0)
Histologic grade c 0.001
I 15 (15.5) 21 (23.9) 0 (0)
II 71 (73.2) 57 (64.8) 7 (53.8)
III 9 (9.3) 10 (11.4) 6 (46.2)
Unknown 2 (2.0) 0 (0) 0 (0)
PR d 0.649
Positive 81 (83.5) 76 (86.4) 10 (76.9)
Negative 16 (16.5) 12 (13.6) 3 (23.1)
Ki-67 c 0.506
≥ 20% 18 (18.6) 15 (17.1) 4 (30.8)
< 20% 79 (81.4) 72 (81.8) 9 (69.2)
Unknown 0 (0.0) 1 (1.1) 0 (0.0)
aχ2 test except b
bKruskal-Wallis test
cMissing value
dPositive, Allred score 2–8; Negative, Allred score 0–1
Data are presented as n (%)
IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma, pN stage: pathologic nodal stage, PR: progesterone receptor, pStage: pathologic stage, pT stage:
pathologic tumor stage, TIL: tumor infiltrating lymphocyte
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associated with a significant change in the chemo-
endocrine treatment rate (p < 0.001, Fig. 4b). Chemo-
endocrine therapy was more frequently performed
among patients with high TILs (chemo-endocrine ther-
apy in 10 [76.9%] and ET alone in 3 [23.1%]) and less
frequently among those with low TILs (chemo-endo-
crine therapy in 24 [27.3%] and ET alone in 64 [72.7%])
or intermediate (chemo-endocrine therapy in 21 [21.6%]
and ET alone in 76 [78.4%]).
Discussion
Many investigators have extensively studied the clinical
value of TILs or RS in breast cancer; however, there are
only a few studies regarding an association between
Oncotype DX-RS and TILs in a specific subset of breast
cancer, ER-positive/HER2-negative breast cancer.
We previously hypothesized that tumors with exten-
sive lymphocytic infiltration might have high RS because
patients with high TIL levels have a higher rate of pCR
to preoperative chemotherapy. Additionally, ER-positive/
HER2-negative patients with high RS derive clinical
benefit from adjuvant chemotherapy. If a positive correl-
ation could be found between the two markers, further
studies testing TIL levels as a biomarker that predicts
clinical benefit for adjuvant chemotherapy in ER-
positive/HER2-negative cancer would be warranted.
In this study, we found a weak correlation between RS
and TIL levels, wherein tumors with high TIL levels
tended to have a higher RS. Moreover, high-TIL tumors
had significantly higher median RS than low- or inter-
mediate TIL tumors. A weak correlation between the
two continuous markers was also observed. However, a
close association between categorical RS and TIL levels
was not observed. In addition, multivariate analysis re-
vealed that RS was not an independent factor associated
with high TIL levels.
These biomarkers are both associated with aggressive
tumor biology, but they depend on different pathways in
tumor progression. RS mainly reflects the biological
characteristics of tumor cells, while TILs are a type of
immune cells, reflecting the immune tumor microenvir-
onment. Therefore, it is not surprising that RS was not
highly correlated with TIL levels in our analysis.
On examining 21 genes in RS, the CD68 is the only
gene obviously associated with immune function in
breast cancer. CD68 is a heavily glycosylated glycopro-
tein that is highly expressed by macrophages and is rec-
ognized as a marker for tumor-associated macrophages
[21]. In a hypothesis-generating study using human
Fig. 1 Scatter plots of continuous recurrence scores and continuous
tumor infiltrating lymphocytes (TILs) (Pearson’s R = 0.201; P = 0.004)
Fig. 2 Distribution of the 21-gene recurrence score (RS) groups according to tumor infiltrating lymphocyte (TIL) count. a Patients with
intermediate-TIL tumors showed a distribution of categorized RS similar to that of patients with low-TIL tumors. In contrast, among the patients
with high-TIL tumors, the percentage of intermediate RS was significantly higher (p = 0.007). b Tumors with higher RS (≥ 26) tended to have a
higher rate of high TIL levels, but it was not significant (p = 0.155)
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breast carcinoma treated with or without neoadjuvant
chemotherapy, CD68 was found to play a role in the im-
mune microenvironment of breast cancer [21]. Specific-
ally, several studies using large cohorts of breast cancer
patients have revealed that the expression of CD68 in
tumor tissue is associated with higher grade [22, 23], in-
creased angiogenesis [24–26], and reduced disease-free
survival [25, 27, 28]. The impact of CD68 expression on
the final 21-gene RS has not been of much interest to re-
searchers. In our study, the relationship between TILs
and CD68 levels remained unexplored. Hence, further
studies correlating CD68 and TIL levels in ER-positive/
HER2-negative cancer will shed light on the tumor-
immune interaction in this subset.
There might be an association between HER2 expres-
sion and TIL levels because there is solid evidence—from
translational studies using tumor samples from prospect-
ive trials—that high TIL levels correlate with response to
anti-HER2 therapy [29] and that patients with HER2-
positive breast cancer receiving adjuvant trastuzumab
Fig. 3 Distributions of recurrence score (RS) according to tumor infiltrating lymphocyte (TIL) levels. a Distributions of RS differed significantly
among the three groups, which were categorized by TIL levels (p = 0.001 with Kruskal-Wallis test). The median RS (interquartile) was 16 (11–23)
in the low-TIL group, 18 (13.25–22.75) in the intermediate-TIL group, and 24 (22–28.5) in the high-TIL group. A post-hoc test with the Bonferroni-
corrected Dunn’s procedure showed that high-TIL tumors had significantly higher median RS than low- or intermediate TIL tumors (p = 0.001 and
p = 0.019, respectively), whereas intermediate-TIL tumors did not have a higher median RS than low-TIL tumors (p = 0.290). b Distributions of RS
differed significantly according to the dichotomized TIL levels (p < 0.001 with Mann-Whitney U test). The median RS was 17 (12.5–23) in the
low- and intermediate-TIL group and 24 (22–28.5) in the high-TIL group. Lines indicate the median values, and error bars indicate
interquartile ranges
Table 2 Binary logistic regression analysis to identify predictive factors for high TIL level
Univariate Multivarite
P-value OR 95% CI P-value OR 95% CI
Nuclear grade < 0.001 0.001
1 or 2 Ref Ref
3 20.308 4.321–95.452 14.950 2.841–78.656
Histologic grade 0.001 0.379
1 or 2 Ref Ref
3 7.857 2.381–25.931 1.882 0.460–7.702
Recurrence Score 0.047 0.750
Low or intermediate Ref Ref
High 2.896 1.001–9.360 1.251 0.315–4.973
TIL: tumor infiltrating lymphocyte, OR: odds ratio, CI: confidence interval
Ahn et al. BMC Cancer  (2018) 18:320 Page 6 of 9
showed improved survival [30]. However, similar to real
practice, we only used 21-gene RS for HER2-negative
cases; hence, it might be difficult to find a link between
TIL levels and HER2 expression in this study.
A growing body of evidence suggests that TIL levels are
associated with the response to chemotherapy via several
distinct mechanisms of the tumor-immune interaction
[2–8]. Chemotherapy can increase the vulnerability of
tumor cells to lytic action by cytotoxic CD8+ T cells, and
selectively reduce circulating regulatory T cells as well as
restore the function of natural killer (NK) cells [31]. Fur-
thermore, the proliferation of T cells and the lytic function
of NK cells were promoted by chemotherapy in breast
cancer patients treated with adjuvant taxanes [32]. These
findings are connected with recent studies showing that
patients with lymphocyte-predominant breast cancer
(LPBC) had a better prognosis compared to non-LPBC
among patients treated with chemotherapy [2, 4, 6]. How-
ever, the association between TIL levels and oncologic
outcome was reproducibly confirmed in TNBC, but not in
ER-positive/HER2-negative breast cancer [2, 4, 6].
A meta-analysis with 1366 HR-positive/HER2-negative
patients receiving NAC found that patients with high
TIL levels had a worse prognosis than patients with low
TIL levels, but a similar outcome compared to patients
with intermediate TIL levels, even though they had a
higher rate of pCR [10]. By contrast, patients with high
RS had worse outcome compared to patients with low
or intermediate RS [11, 12]. Taken together with our
data, it appears that RS and TIL levels stratify patients
into subgroups based on different tumor biology. TIL
levels are relatively low in ER-positive/HER2-negative
tumors than in other subtypes. Although inconsistent
cut-off points (50% or 60%) have been applied to define
high TIL levels, the rate of high-TIL tumors is 2.9%–13%
in ER-positive/HER2-negative patients [6, 10]. Our data
are in line with these findings, with a rate of high-TIL
tumors of only 6.6% (13 of 198; cut-off of 60%).
The relationship between endocrine responsiveness
and the degree of TILs needs to be explored. Recently,
Dieci et al. evaluated the association between TIL levels
in core biopsies and Ki-67 suppression after letrozole
treatment with/without lapatinib for 24 weeks [33]. They
found that patients with high TIL levels (cut-off of 10%)
more frequently had a relative Ki-67 suppression ≥50%
from baseline compared to patients with low TIL levels,
without statistical significance (55% vs. 35%). Dunbier et
al. showed that an inflammatory signature is associated
with a poor response to 2-week aromatase inhibitor
treatment, implying that TIL levels might be associated
with endocrine resistance [34]. Further clinical and pre-
clinical research should be performed.
Previously, Krishnamurti et al. compared TIL levels
with RS in ER-positive cancer [35], and their study
shows several differences from ours. Krishnamurti et al.
did not exclude HER2-positive tumors from ER-positive
tumors, whereas we only included ER-positive/HER2-
negative tumors because the RS assay is applied clinic-
ally for those specific tumors. Moreover, the TIL level
cut-offs are different between the studies. Krishnamurti
et al. set the high TIL cut-off of as 50%, whereas we set
ours at 60%, per the study by Denkert [10]. In addition,
Krishnamurti et al. showed a negative correlation
between TIL levels and RS, implying that TIL is a favor-
able marker that differs from our study. Further studies
with larger cohorts are required to determine the
prognostic effects of TIL levels in ER-positive/HER2-
negative breast cancer.
Fig. 4 Association of TIL levels with RS-guided adjuvant therapy. a The proportions of adjuvant treatments according to RS (p < 0.001). b The
proportions of adjuvant treatments according to TIL levels (p < 0.001)
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A major limitation of our study, in addition to the
short follow-up duration, is the absence of survival ana-
lyses among the groups divided by the two markers. The
clinical outcomes of our study population might help re-
fine prognostic discrimination according to these
markers. Additionally, evaluation of TIL levels could dif-
fer according to the type of sample, such as core biopsies
or surgical specimens. In this study, we evaluated the
TIL levels using only surgically resected samples, but
several studies used samples from core biopsies. Despite
these limitations, our analysis comparing RS and TIL
levels lays the groundwork for future research on the
tumor-immune interaction in ER-positive/HER2-nega-
tive breast cancer.
Intriguingly, in our patients receiving RS-guided treat-
ments, chemotherapy was more frequently performed
among patients with high TILs and less frequently
among those with low or intermediate TILs. Further
studies are required considering the clinical outcomes to
determine whether TIL levels could clinically benefit
chemotherapy for endocrine-sensitive tumors.
Conclusions
Despite of a very weak correlation between continuous
TIL levels and RS, we found that tumors with high TIL
levels tended to have a higher RS in ER-positive/HER2-
negative breast cancer. Further study is warranted con-
sidering the clinical outcomes. The role of the tumor-
immune interaction in ER-positive breast cancer needs
to be explored in the future studies.
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